Calendar

Join the inaugural event of AMCP’s AI LINK Interest Group and explore how artificial intelligence is transforming managed care pharmacy. We’ll dive into why standardized frameworks are essential to evaluate AI-driven solutions and how transparent, interoperable tools can help payors make informed, safe, and efficient coverage decisions. Not in an AMCP LINK yet? AMCP members can sign up now. 

Guest Experts: 

• Brenton Hill, JD, MHA - CHAI 
• Keith Kallmes - Knested Knowledge 
• Adam Colborn, JD - AMCP

Pre-Approval Information Exchange presentation for investigational revumenib, including a clinical overview, burden of disease, and disease background for pediatric and adult patients with NPM1-mutated relapsed or refractory acute myeloid leukemia.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This webinar highlights an introduction to Scholar Rock, an emerging biopharmaceutical company, and provides an overview of the Spinal Muscular Atrophy (SMA) disease landscape, remaining unmet needs in SMA, and apitegromab clinical data.

Advance understanding of the importance of frequent monitoring risk level of pulmonary arterial hypertension (PAH) and right heart monitoring. Explore and discuss the importance of timely escalation of therapies in the treatment of PAH. Participants will learn about the significant role risk stratification plays in informing providers' treatment decisions, as well as the importance of right heart and hemodynamic considerations in conjunction with risk assessment.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Crohn's disease and ulcerative colitis are chronic autoimmune disorders associated with major clinical and economic burden. The American College of Gastroenterology (ACG) recently released updates to their clinical guidelines for the Management of Crohn's Disease (CD) and Ulcerative Colitis (UC) in Adults. Both guidelines incorporate available evidence to provide recommendations for the treatment and prevention of complications associated with inflammatory bowel disease (IBD). The objective of this webinar is to highlight guideline updates and provide suggestions for application of the recommendations into practice and payer policy.

By the end of this session, attendees will be able to:

• Recognize the significant unmet medical need in the Macular Telangiectasia Type 2 (MacTel), including clinical characteristics, disease progression and implications of delayed or absent treatment.
• Understand the patient journey where patients often navigate through subtle, inconsistent symptoms that affect their activities of daily living and quality of life prior to obtaining a definitive diagnosis.
• Explain the mechanism of action, clinical efficacy, safety profile, and long-term durability of ENCELTO, emphasizing the cell-based gene therapy's ability to address the underlying pathophysiology of MacTel.
• Assess key factors impacting patient access to ENCELTO and potential solutions to balance affordability concerns with appropriate access to treatment.

Significant policy changes under the new presidential administration are set to impact various healthcare sectors. Upstream influences demand a strategic reevaluation of global supply chains and competitive positioning, while downstream effects will reshape how organizations and communities engage with and serve local populations.

This session will examine the evolving policy landscape and its implications for stakeholders in managed care pharmacy and the biopharmaceutical industry. Through expert insights and dynamic discussion, attendees will gain a practical framework to navigate emerging challenges and opportunities, empowering informed decision-making in a rapidly changing healthcare environment.